Towards a tripple oral therapy in the pharmacological treatment of type 2 diabetes?;Vers une trithérapie orale dans le traitement pharmacologique du diabète de type 2?

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 414-418

  Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Combined therapy; Glitazone; Metformin; Sulphonylurea; Thiazolidinedione; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; METFORMIN; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 21744459274     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Scheen AJ.- Pathophysiology of type 2 diabetes. Acta Clin Belg, 2003, 58, 335-341.
2. Fery F, Paquot N.- Physiopathologie du diabète de type 2. Rev Med Liège, 2005, 60, 361-368.
3. DeFronzo RA.- The triumvirate: B-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes, 1988, 37, 667-687.
4. Scheen AJ, Lefèbvre PJ.- Insulin resistance vs. insulin deficiency: which comes first? The old question revisited. In: Diabetes in the New Millennium (Eds: Di Mario U et al), J. Wiley & Sons, New York, 2000, 101-113.
5. Reaven GM.- The fourth Musketeer - from Alexandre Dumas to Claude Bernard. Diabetologia, 1995, 38, 3-13.
6. Paquot N, Tappy L.- Les adipocytokines: lien entre obésité, diabète de type 2 et athérosclérose?. Rev Med Liège, 2005, 60, 369-373
7. Scheen AJ, Lefèbvre PJ.- Oral antidiabetic drugs: a guide to selection. Drugs, 1998, 55, 225-236.
8. Scheen AJ.- Treatment of type 2 diabetes. Acta Clin Belg, 2003, 58, 318-324.
9. Davidson MB.- Triple therapy. Definitions, application, and treating to target. Diabetes Care, 2004, 27, 1834-1835.
10. Inzucchi SE.- Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA, 2002, 287, 360-372.
11. Radermecker RP.- Place des insulinosécrétagogues dans le traitement de type 2. Rev Med Liège, 2005, 60, 402-408.
12. Scheen AJ, Paquot N.- Les insulinosensibilisateurs. Rev Med Liège, 2005, 60, 409-413.
13. Girard J.- Mécanisme d'action des thiazolidinediones. Diabetes Metab, 2001, 27, 271-278.
14. Van Gaal LF, De Leeuw IH.- Rationale and options for combination therapy in the treatment of Type 2 diabetes. Diabetologia, 2003, 46 (Suppl 1), M44-M50.
15. Ahmann AJ, Riddle MC.- What to do when two oral agents fail to control type 2 diabetes - A matter of opinion or a matter of fact? Am J Med, 2004, 116, 276-278.
16. Yale JF, Valiquett TR, Ghazzi MN, et al for the Troglitazone Triple-Therapy Study Group.- The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. Ann Intern Med, 2001, 134, 737-745.
17. Jones N, Jones T, Menci L, et al.- Rosiglitazone in combination with glibenclamide plus metformin is effective and well tolerated in type 2 diabetes patients (abstract). Diabetologia, 2001, 44 (Suppl 1), A904.
18. Kiayias JA, Vlachou ED, Theodosopoulou E, et al.- Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care, 2002, 25, 1251-1252.
19. Byrne J, Garg S, Vaidya A, et al.- Efficacy of triple combination oral therapy using rosiglitazone, metformin, and sulphonylurea in lowering HbA1c. Pract Diab Int, 2003, 20, 58-60.
20. Dailey GE, Noor MA, Park J-S, et al.- Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med, 2004, 116, 223-229.
21. Roy R, Navar M, Palomeno G, et al.- Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population. Diabetes Care, 2004, 27, 1741-1742.
22. Bell DSH, Ovalle F.- Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract, 2002, 8, 271-275.
23. Schwartz S, Sievers R, Strange P, et al.- Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost-analysis. Diabetes Care, 2003, 26, 2238-2243.
24. Aljabri K, Kozak SE, Thompson DM.- Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med, 2004, 116, 230-235.
25. Rosenstock J, Sugimoto D, Strange P, et al.- Triple therapy in type 2 diabetes (T2DM): benefits of insulin glargine (GLAR) over rosiglitazone (RSG) added to combination therapy of sulfonylurea plus metformin (SU+MET) in insulin-naive patients (abstract). Diabetes, 2004, 53 (Suppl 2), A145
26. Scheen AJ.- Pièges et conseils à propos de l'utilisation des antidiabétiques oraux conventionnels. Rev Med Liège, 2002, 57, 352-356.
27. Inzucchi SE, Maggs DG, Spollett GR, et al.- Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med, 1998, 338, 867-872.
28. Virtanen KA, Hällsten K, Parkkola R, et al.- Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes, 2003, 52, 283-290.
29. Braunstein S.- New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione. Clin Ther, 2003, 25, 1895-1917.
30. Scheen AJ.- La non-observance thérapeutique: problème majeur pour la prévention des maladies cardiovasculaires. Rev Med Liège, 1999, 54, 914-920.
31. Bailey CJ, Day C.- Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes. Int J Clin Pract, 2004, 58, 867-876.
32. Del Prato S, Volpe L.- Rosiglitazone plus metformin: combination therapy for Type 2 diabetes. Expert Opin Pharmacother, 2004, 5, 1411-1422.
33. Scheen AJ.- Glucovance® dans le diabète de type 2, une association fixe metformine-glibenclamide pour faciliter le traitement d'une maladie bipolaire. Rev Med Liège, 2003, 58, 448-452.
34. Davidson JA, Scheen AJ, Howlett HCS.- Tolerability profile of metformin/glibenclamide combination tablets (Glucovance®). A new treatment for the management of type 2 diabetes mellitus. Drug Safety, 2004, 27, 1205-1216.
35. Barnett AH.- Triple oral antidiabetic therapy in type 2 diabetes. Diabet Med, 2003, 20 (Suppl 1), 14-16.
36. Slama G.- Pourquoi faut-il tendre vers une polychimiothérapie systématique précoce chez les diabétiques de type 2. In: Journées Annuelles de Diabétologie de l'Hôtel-Dieu, Paris, Flammarion Médecine Sciences, 2001, 214-228.
37. Walter H, Lubben G.- Potential role of oral thiazolidinedione therapy in preservation of beta-cell function in type 2 diabetes mellitus. Drugs, 2005, 65, 1-13.
38. Martens FM, Visseren FL, Lemay J, et al.- Metabolic and additional vascular effects of thiazolidinediones. Drugs, 2002, 62, 1463-1480.
39. Numéro spécial.- Cardiovascular benefits of metformin. Diabetes Metab, 2003, 29, 6S5-6S122.